<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872219</url>
  </required_header>
  <id_info>
    <org_study_id>HelsinkiUAdele2poc</org_study_id>
    <nct_id>NCT03872219</nct_id>
  </id_info>
  <brief_title>Biodiversity Intervention and Atopic Sensitization</brief_title>
  <acronym>PREVALL</acronym>
  <official_title>The Effect of Plant and Soil-based Material on the Incidence of Atopic Sensitization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tampere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pirkanmaa Hospital District (Pirkanmaan sairaanhoitopiiri)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Business Finland (National Innovation Agency)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Helsinki</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children will receive biodiversity intervention or placebo. The proof of concept trial is
      double blind. Intervention will start at the age of 2 months and last 10 months. Children
      will be randomized to arms. IgE sensitization is the primary outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Newborns will start to be exposed to biodiversity intervention or placebo at the age of two
      months. The proof of concept trial will be double blind. Intervention will start at the age
      of 2 months and it will end when children become 12 months old. Children will be randomized
      to the two arms. IgE sensitization is the primary outcome at the age of two and three years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 25, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study consists of two arms, the intervention arm and the placebo arm. Children are randomized into the arms.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind randomized trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>IgE sensitization</measure>
    <time_frame>2-3 years</time_frame>
    <description>IgE sentitization is expected to be lower in the intervention arm than in the placebo arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Allergic symptoms</measure>
    <time_frame>2-3 years</time_frame>
    <description>All possible allergic symptomes, including atopy, will be estimated</description>
  </secondary_outcome>
  <other_outcome>
    <measure>IL-10: IL-17 ratio</measure>
    <time_frame>2-3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>TGF-beta level</measure>
    <time_frame>2-3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>IL-10 levels</measure>
    <time_frame>2-3 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Atopy</condition>
  <condition>Allergy</condition>
  <condition>Allergic Rhinitis</condition>
  <condition>Allergic Sensitisation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The children will receive and they are exposed daily to harmless materials that look and feel like the biodiversity intervention materials.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The children will receive and they are exposed daily to materials of high microbiological biodiversity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Nature-based materials</intervention_name>
    <description>In the intervention arm, theycontain inactive and slowly-growing environmental bacteria and other microbiota. In the placebo arm, they do not contain the microbiota.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>intervention arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  both parents have atopy

          -  newborn

        Exclusion Criteria:

          -  severe disease, particularly immune system deficiency or down syndrome or cancer

          -  medication affecting immune system

          -  birth before week 35 in pregnancy

          -  being a twin

          -  only one of the parents have atopy

          -  none of the parents have atopy

          -  children have passed the age of two months

          -  immune system disorder such as rheumatoid disease, colitis ulcerosa, Crohn disease,
             diabetes or genetic risk to type 1 diabetes

          -  no participation in national vaccination programme
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aki Sinkkonen</last_name>
    <phone>358 2941 20315</phone>
    <email>aki.sinkkonen@helsinki.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Riikka Puhakka</last_name>
    <phone>358 50 3199363</phone>
    <email>riikka.puhakka@helsinki.fi</email>
  </overall_contact_backup>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Helsinki</investigator_affiliation>
    <investigator_full_name>Aki Sinkkonen</investigator_full_name>
    <investigator_title>University Researcher</investigator_title>
  </responsible_party>
  <keyword>biodiversity intervention</keyword>
  <keyword>IgE</keyword>
  <keyword>atopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will share it according to Finnish legislation and ethical committee permission. The permission restrict sharing tightly.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

